NASDAQ$MDXG

Mimedx Group Inc · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

Reported a slight decrease in net sales but double-digit revenue increase in continuing portfolio, and a net loss compared to the prior year period.

MiMedx Group, Inc. announced its first quarter 2022 results, with net sales of $58.9 million, a slight decrease compared to the prior year. However, the continuing portfolio of tissue and cord products experienced a 13% increase in revenue. The company reported a net loss of $10.5 million for the quarter.

  • Net sales decreased slightly to $58.9 million compared to $60.0 million in the prior year quarter.
  • Continuing portfolio of tissue and cord products increased 13% year-over-year.
  • Net loss was $10.5 million, compared to a net loss of $8.4 million for the prior year period.
  • Advanced Wound Care products drove double-digit growth for the third consecutive quarter.

Headline financials

Total Revenue

$58.9M

Previous: $60M-1.8%
EPS (adj)

-$0.11

Previous: -$0.09-22.2%
Capital Expenditures

-$118K

Previous: -$1.94M+93.9%
Free Cash Flow

-$10.6M

Previous: -$10.3M-2.8%
Net Income

-$10.5M

Previous: -$8.38M-25.1%
Operating Income

-$9.3M

Previous: -$6.85M-35.7%
Gross Profit

$49M

Previous: $50.3M-2.7%
Cash & Equivalents

$75.7M

Previous: $84.7M-10.7%
Total Assets

$174M

Previous: $191M-8.6%
Stock-Based Comp

$4M

Previous: $3.24M+23.2%

Revenue & EPS history

Mimedx · Revenue · Quarterly

$58.9M

Q1 2022-1.8%vs Q1 2021
Beat estimate in 8 of 10 quarters(80%)
ActualEstimate

Forward guidance

The Company maintained its outlook for 2022, as disclosed in its earnings release for the year ended December 31, 2021, including that it expects net sales of its continuing portfolio of Advanced Wound Care products, which were $240.0 million in 2021, to grow 11% to 14% in 2022, as it plans to launch EPIFIX in Japan, as well as two new products in the U.S., AMNIOEFFECT and its Placental Collagen Matrix product, later this year.

Tailwinds

  • Plans to launch EPIFIX in Japan.
  • Plans to launch AMNIOEFFECT in the U.S.
  • Plans to launch Placental Collagen Matrix product in the U.S.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

+1.7%

Avg return

Earnings day

+2.9%

Avg return

5 days after

+7.2%

Avg return

30 days after

53%

34 / 64 earnings

Positive

+37.9%

Q1 2023

Best reaction

-23.3%

Q3 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-9.1%+6.2%+8.2%
Q4 2025-0.9%-8.8%-28.8%
Q3 2025+2.6%+7.0%-4.3%
Q1 2025-8.1%-3.9%-6.5%
Q4 2024+1.6%+1.1%-5.9%
Q3 2024+17.9%+22.7%+59.2%
Q2 2024-12.0%-17.7%-9.9%
Q1 2024+16.8%+17.7%+13.7%
Q4 2023-2.9%-1.7%-8.3%
Q3 2023+6.7%+10.9%+26.5%
Q2 2023-4.6%-4.2%-8.1%
Q1 2023+37.9%+49.1%+50.4%
Q4 2022-11.4%-6.4%-29.0%
Q3 2022-3.6%+1.3%+12.6%
Q2 2022+8.2%+15.5%+2.3%
Q1 2022+11.1%-8.9%-4.8%
Q4 2021+1.4%-1.6%-4.0%
Q3 2021+18.8%+22.6%+2.5%
Q2 2021-2.5%+1.4%+23.4%
Q1 2021-2.9%-5.0%+2.0%
Q4 2020-15.3%-13.4%+13.8%
Q3 2020+3.4%-8.2%-5.6%
Q2 2020+2.3%+4.2%+14.4%
Q2 2018+8.2%+3.2%+18.2%
Q1 2020+8.2%+3.2%+18.2%
Q4 2018+8.2%+3.2%+18.2%
Q4 2019+8.2%+3.2%+18.2%
Q2 2019+8.2%+3.2%+18.2%
Q1 2018+8.2%+3.2%+18.2%
Q1 2019+8.2%+3.2%+18.2%
Q3 2019+8.2%+3.2%+18.2%
Q4 2017-21.6%-22.1%-14.0%
Q3 2018-1.3%-8.6%-7.0%
Q3 2017+4.1%+8.7%-4.9%
Q2 2017+0.7%+2.1%+5.9%
Q1 2017+8.2%+19.1%+17.5%
Q4 2016-3.9%+3.4%+9.8%
Q3 2016+4.9%+8.0%+19.1%
Q2 2016-0.9%-1.7%-5.6%
Q1 2016-1.4%
Q4 2015-0.4%
Q3 2015-23.3%
Q2 2015-13.5%
Q1 2015+0.9%
Q4 2014+8.7%
Q3 2014+13.2%
Q2 2014+5.5%
Q1 2014-3.8%
Q4 2013+2.2%
Q3 2013-3.5%
Q2 2013+0.8%
Q1 2013-2.2%
Q4 2012+8.5%
Q3 2012+13.5%
Q2 2012-4.8%
Q1 2012+0.0%
Q4 2011+0.0%
Q3 2011-4.2%
Q2 2011-2.5%
Q1 2011-3.7%
Q4 2010+5.8%
Q3 2010+0.0%
Q2 2010-4.8%
Q1 2010+4.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro